This report provides an overview of the global market for targeted alpha therapies for cancer and analyses market trends. It includes global revenue ($ millions) for the base year data 2024 and estimated data for 2025, forecasted CAGRs through 2030.
The report provides an overview of the global market for targeted alpha therapies (TAT) for cancer and analyzes market trends. It includes global revenue ($ million) for the base year data 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented based on cancer type.
The report focuses on trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report includes an analysis of the competitive landscape and pipeline analysis. A section dedicated to company profiles addresses key financials, product portfolios and recent developments involving industry leaders.
The report provides an overview of the global market for targeted alpha therapies (TAT) for cancer and analyzes market trends. It includes global revenue ($ million) for the base year data 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented based on cancer type.
Report Scope
The report provides an overview of the global market for targeted alpha therapies (TAT) for cancer and analyzes market trends. It includes global revenue ($ million) for the base year data 2024 and estimated data for the forecast period 2025 through 2030. The market is segmented based on cancer type.The report focuses on trends and challenges that affect the market and vendor landscape. It analyzes corporate environmental, social and governance (ESG) developments and discusses emerging technologies related to the market. The report includes an analysis of the competitive landscape and pipeline analysis. A section dedicated to company profiles addresses key financials, product portfolios and recent developments involving industry leaders.
Report Includes
- Overview and an analysis of the global market for targeted alpha therapies (TAT) for cancer treatment
- Analyses of the global market trends, with historical market revenue data from 2022 to 2024, estimates for 2025, and projections of CAGRs through 2030
- Estimates of the current market size and revenue prospects of the global market, accompanied by a market share analysis by cancer type and region
- Facts and figures pertaining to market dynamics, technological advances, regulations, prospects and the impacts of macroeconomic variables
- Insights derived from Porter’s Five Forces model, and information on emerging trends and technologies, latest developments, and product pipeline analysis
- Overview of sustainability trends and ESG developments, with emphasis on consumer attitudes, as well as the ESG risk ratings and practices of leading companies
- A relevant patent analysis, featuring key granted and published patents
- Analysis of the industry structure, including companies’ market shares and rankings, strategic initiatives, M&A activity and a venture funding outlook
- Profiles of the leading companies
Table of Contents
Chapter 1 Executive Summary
Chapter 2 Market Overview
Chapter 3 Market Dynamics
Chapter 4 Regulatory Landscape
Chapter 5 Emerging Technologiesand Developments
Chapter 6 Market Segmentation Analysis
Chapter 7 Competitive Intelligence
Chapter 8 Sustainability in Targeted Alpha Therapies for Cancer Treatment Market: An ESG Perspective
Chapter 9 Appendix
List of Tables
List of Figures
Companies Mentioned
- Actinium Pharmaceuticals Inc.
- Advancell Pty Ltd.
- Bayer Ag
- Convergent Therapeutics Inc.
- Fusion Pharm
- Novartis Ag
- Orano Med
- Perspective Therapeutics
- Radiomedix Inc.
- Rayzebio Inc.
